PRIME designation granted by European Medicines Agency for Roche ’s risdiplam for treatment of spinal muscular atrophy (SMA)
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational oral medicine risdiplam (RG7916) for the treatment of people with SMA. (Source: Roche Investor Update)
Source: Roche Investor Update - December 17, 2018 Category: Pharmaceuticals Source Type: news

New member proposed for election to Roche Board of Directors
Roche today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Corporate Executive Committee
Roche today announced that Daniel O ’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2018 Category: Pharmaceuticals Source Type: news

Chugai Receives Orphan Drug Designation for TECENTRIQ ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors
(Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2018 Category: Pharmaceuticals Source Type: news

Chugai Presents Interim Analysis Data of Phase I/II Study of SKY59, anti-C5 antibody in PNH at ASH
(Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks). (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s live audio webcast at the 2018 American Society of Hematology’s 60 th Annual Meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 4 December 2018, highlighting the results from important clinical studies which Roche will present at the upcoming American Society of Hematology (ASH) 60th Annual meeting in San Diego, California, from 1-5th December. (Source: Roche Investor Update)
Source: Roche Investor Update - November 27, 2018 Category: Pharmaceuticals Source Type: news

FDA approves the ACTPen for Roche ’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved ACTPen ™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra®(tocilizumab) as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), and for adul t patients with giant cell arteritis (GCA). (Source: Roche Investor Update)
Source: Roche Investor Update - November 26, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - November 21, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Investor Update)
Source: Roche Investor Update - November 13, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Roche today announced that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting from 1-4 December, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's live audio webcast at the 2018 American Society of Hematology's 60th Annual Meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 4 December 2018, highlighting the results from important clinical studies which Roche will present at the upcoming American Society of Hematology (ASH) 60th Annual meeting in San Diego, California, from 1-5th December. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)
Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche today announced that the US Food and Drug Administration (FDA) has approved Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - October 24, 2018 Category: Pharmaceuticals Source Type: news

Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78%Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system by 86%Data add to a wealth of evidence, includ (...) (Source: Roche Investor Update)
Source: Roche Investor Update - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Roche will today announce results from the phase III ALESIA study, showing that Alecensa ® (alectinib) met its primary endpoint of investigator-assessed (INV) progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche today announced positive results from the Phase III IMpower130 study of Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy help ed people live significantly longer compared to chemotherapy alone (median overall survival [OS] =18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) populatio...
Source: Roche Investor Update - October 22, 2018 Category: Pharmaceuticals Source Type: news

Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC)
Roche will today present updated data from a Phase Ib study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable or advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 21, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Roche today announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours. (Source: Roche Investor Update)
Source: Roche Investor Update - October 21, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Investor Update)
Source: Roche Investor Update - October 20, 2018 Category: Pharmaceuticals Source Type: news

FDA approves label update for Roche ’s Mabthera/Rituxan (rituximab) in two rare forms of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the MabThera/Rituxan ® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) who have achieved disease control with induction treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 19, 2018 Category: Pharmaceuticals Source Type: news

Roche reports very strong growth in the first nine months of 2018
Group sales increase 7% at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Alecensa and Tecentriq. Diagnostics Division sales grow 6%, primarily due to demand for immunodiagnostic solutions. (Source: Roche Investor Update)
Source: Roche Investor Update - October 17, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 22 October 2018, to discuss key data presented on the Roche Group's oncology portfolio pipeline during the ESMO 2018 Congress in Munich, Germany, from 19-23 October 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2018 Category: Pharmaceuticals Source Type: news

Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018
(Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
Roche today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO Tumor Tissue Targeted Kit, Expanded Kit and Surveillance Kit. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's 9 Months Sales 2018 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2018 prior to the opening of the Swiss Stock Exchange on Wednesday, October 17th, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - October 10, 2018 Category: Pharmaceuticals Source Type: news

OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from 10 October to 12 October in Berlin, Germany. (Source: Roche Investor Update)
Source: Roche Investor Update - October 10, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
Roche today announced that new results from a number of studies across its industry leading oncology portfolio of approved and investigational medicines will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place from 19-23 October, in Munich, Germany. (Source: Roche Investor Update)
Source: Roche Investor Update - October 9, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors
Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - October 4, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 22 October 2018, to discuss key data presented on the Roche Group ’s oncology portfolio and pipeline during the ESMO 2018 Congress in Munich, Germany, from 19-23 October 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - October 4, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Roche today announced that the phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median time of 73.2 hours versus 102.3 hours; p (Source: Roche Investor Update)
Source: Roche Investor Update - October 4, 2018 Category: Pharmaceuticals Source Type: news

Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche today announced interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in SMA. (Source: Roche Investor Update)
Source: Roche Investor Update - October 3, 2018 Category: Pharmaceuticals Source Type: news

Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany, 10 to 12 October. (Source: Roche Investor Update)
Source: Roche Investor Update - October 2, 2018 Category: Pharmaceuticals Source Type: news

FDA grants approval of Xolair (omalizumab) prefilled syringe formulation
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes (PFS) for Xolair ® (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications. (Source: Roche Investor Update)
Source: Roche Investor Update - October 1, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Roche today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Roche announced today the global availability of FoundationOne ®Liquid, a liquid biopsy test. (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra ® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 25 September 2018, highlighting the results from important clinical studies which Roche will present at the upcoming IASLC World Conference on Lung Cancer in Toronto, Canada, from the 23-25th September. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
Roche today announced the launch of the first two NAVIFY ® clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps help oncology care teams access relevant clinical trial information and publications more effectively. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2018 Category: Pharmaceuticals Source Type: news